Clinical Trial Highlights: Modulators of Mitochondrial Function

Overview

Journal J Parkinsons Dis

Publisher Sage Publications

Specialty Neurology

Date 2023 Sep 11

PMID 37694310

Authors

Francesco Capriglia

Toby Burgess

Oliver Bandmann

Heather Mortiboys

Affiliations

Soon will be listed here.

Citing Articles

Reversing Signs of Parkinsonism in a Cell Model Using Mitochondria-Targeted Organoiridium Catalysis.

Jana R, Nguyen H, Yan G, Chen T, Do L J Med Chem. 2025; 68(2):1970-1983.

PMID: 39749732 PMC: 11757046. DOI: 10.1021/acs.jmedchem.4c02741.

References

Mann V, Cooper J, Krige D, Daniel S, Schapira A, Marsden C . Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain. 1992; 115 ( Pt 2):333-42. DOI: 10.1093/brain/115.2.333. View

Haji S, Fujita K, Oki R, Osaki Y, Miyamoto R, Morino H . An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study. JMIR Res Protoc. 2023; 12:e42032. PMC: 9926342. DOI: 10.2196/42032. View

Wang Q, Xu Y, Liu S, Ma Z . Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice. Oncotarget. 2017; 8(29):47284-47295. PMC: 5564564. DOI: 10.18632/oncotarget.17618. View

Storch A . [Coenzyme Q10 in Parkinson's disease. Symptomatic or neuroprotective effects?]. Nervenarzt. 2007; 78(12):1378-82. DOI: 10.1007/s00115-007-2285-1. View

. Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial. Ann Intern Med. 2020; 172(9):591-598. PMC: 7465126. DOI: 10.7326/M19-2534. View

Castelo Rueda M, Zanon A, Gilmozzi V, Lavdas A, Raftopoulou A, Delcambre S . Molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous PRKN variant carriers. NPJ Parkinsons Dis. 2023; 9(1):65. PMC: 10113363. DOI: 10.1038/s41531-023-00499-9. View

Papkovskaia T, Chau K, Inesta-Vaquera F, Papkovsky D, Healy D, Nishio K . G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization. Hum Mol Genet. 2012; 21(19):4201-13. PMC: 3441120. DOI: 10.1093/hmg/dds244. View

Yoshino H, Nakagawa-Hattori Y, Kondo T, Mizuno Y . Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1992; 4(1):27-34. DOI: 10.1007/BF02257619. View

Cardellach F, Marti M, Fernandez-Sola J, Marin C, Hoek J, Tolosa E . Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. Neurology. 1993; 43(11):2258-62. DOI: 10.1212/wnl.43.11.2258. View

10.

Antony P, Kondratyeva O, Mommaerts K, Ostaszewski M, Sokolowska K, Baumuratov A . Fibroblast mitochondria in idiopathic Parkinson's disease display morphological changes and enhanced resistance to depolarization. Sci Rep. 2020; 10(1):1569. PMC: 6994699. DOI: 10.1038/s41598-020-58505-6. View

11.

Tinker R, Lim A, Stefanetti R, McFarland R . Current and Emerging Clinical Treatment in Mitochondrial Disease. Mol Diagn Ther. 2021; 25(2):181-206. PMC: 7919238. DOI: 10.1007/s40291-020-00510-6. View

12.

Ajith T, Sudheesh N, Roshny D, Abishek G, Janardhanan K . Effect of Ganoderma lucidum on the activities of mitochondrial dehydrogenases and complex I and II of electron transport chain in the brain of aged rats. Exp Gerontol. 2008; 44(3):219-23. DOI: 10.1016/j.exger.2008.11.002. View

13.

Zhou L, Wang W, Hoppel C, Liu J, Zhu X . Parkinson's disease-associated pathogenic VPS35 mutation causes complex I deficits. Biochim Biophys Acta Mol Basis Dis. 2017; 1863(11):2791-2795. PMC: 5659972. DOI: 10.1016/j.bbadis.2017.07.032. View

14.

Su Y, Qi X . Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation. Hum Mol Genet. 2013; 22(22):4545-61. DOI: 10.1093/hmg/ddt301. View

15.

Espay A, Schwarzschild M, Tanner C, Fernandez H, Simon D, Leverenz J . Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. Mov Disord. 2017; 32(3):319-324. PMC: 5359057. DOI: 10.1002/mds.26913. View

16.

Flinn L, Keatinge M, Bretaud S, Mortiboys H, Matsui H, De Felice E . TigarB causes mitochondrial dysfunction and neuronal loss in PINK1 deficiency. Ann Neurol. 2013; 74(6):837-47. PMC: 4154126. DOI: 10.1002/ana.23999. View

17.

Ryan S, Dolatabadi N, Chan S, Zhang X, Akhtar M, Parker J . Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1α transcription. Cell. 2013; 155(6):1351-64. PMC: 4028128. DOI: 10.1016/j.cell.2013.11.009. View

18.

Shaltouki A, Sivapatham R, Pei Y, Gerencser A, Momcilovic O, Rao M . Mitochondrial alterations by PARKIN in dopaminergic neurons using PARK2 patient-specific and PARK2 knockout isogenic iPSC lines. Stem Cell Reports. 2015; 4(5):847-59. PMC: 4437475. DOI: 10.1016/j.stemcr.2015.02.019. View

19.

Mortiboys H, Aasly J, Bandmann O . Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease. Brain. 2013; 136(Pt 10):3038-50. DOI: 10.1093/brain/awt224. View

20.

. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007; 68(1):20-8. DOI: 10.1212/01.wnl.0000250355.28474.8e. View